Satoshi Katayama

27PUBLICATIONS
95CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsPredictive and prognostic markersChemotherapyCentral nervous system
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Oct 26, 2026
Real-World Characteristics and Early Outcomes of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma.

|Oct 20, 2026
Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma.

|Mar 25, 2026
Prognostic value of the modified Glasgow Prognostic Score and Prognostic Nutritional Index in prostate cancer treated with cabazitaxel.

Takuma Kato, Yoichiro Tohi, Atsushi Takamoto

|Dec 26, 2025
Prognostic nutritional index predicts the prognostic impact of avelumab maintenance therapy in patients with advanced urothelial carcinoma: results from the Chu-shikoku Japan Urological Consortium.

Hideo Fukuhara, Shingo Nishimura, Keita Kobayashi

|Oct 22, 2025
An inadequate number of first-line chemotherapy cycles provides poor survival outcomes in patients with metastatic urothelial carcinoma receiving avelumab maintenance: results from the chu-shikoku Japan urological consortium.

Satoshi Katayama, Takehiro Iwata, Shingo Nishimura

|Sep 25, 2025
Needlestick Injury During Urological Surgery: A 15-Year Review From a Multi-Institutional Study in the Chugoku-Shikoku Japan Urological Consortium.

Yutaro Sasaki, Satoshi Katayama, Yoichiro Tohi

Pageof 5

Frequent Collaborators

9 joint publications

Keiichiro Mori

8 joint publications

Ekaterina Laukhtina

7 joint publications

Motoo Araki

6 joint publications

Benjamin Pradere